Virpax Pharmaceuticals Reports 2024 Second Quarter Results and Recent Developments
Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (
NASDAQVRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and viral barrier indications, today announced its financial results for the three months ended June 30, 2024, and other recent developments.
Virpax Pharmaceuticals to Present at LD Micro Invitational XI Event on Wednesday, June 9th at 4:30 PM ET
Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (
NASDAQVRPX), a company specializing in developing non-addictive, non-opioid pharmaceutical products for pain management, today announced that it will be presenting virtually at the upcoming LD Micro Invitational XI event on Wednesday, June 9, 2021 at 4:30 PM ET. Anthony Mack, Chairman and CEO of Virpax, will be giving the presentation.
